Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia

Authors George G Zhanel, Tamiko Hisanaga, Aleksandra Wierzbowski, Daryl J Hoban

Published 15 March 2006 Volume 2006:2(1) Pages 59—75

George G Zhanel, Tamiko Hisanaga, Aleksandra Wierzbowski, Daryl J Hoban

Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada; Departments of Clinical Microbiology and Medicine, Health Sciences Centre, Winnipeg, Canada

Abstract: Acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP) are common conditions and constitute a substantial socioeconomic burden. The ketolides are a new class of antibacterials with a targeted spectrum of antibacterial activity. In vitro, telithromycin is active against common bacterial pathogens that cause upper and lower respiratory tract infections, including some isolates that are resistant to other antibiotic classes. In 2004, telithromycin was the first ketolide antibiotic approved for clinical use by the US Food and Drug Administration for the treatment of adult outpatients with ABS, AECB, and mild-to-moderate CAP. This review discusses the use of telithromycin in the treatment of these infections, providing an overview of its antibacterial activity, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability–safety, and concludes that telithromycin is an appropriate option for the treatment of community-acquired ABS, AECB, and mild-to-moderate CAP.


Keywords: telithromycin, respiratory tract infection, ketolide

Download Article [PDF] 

Readers of this article also read:

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]

Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkær-Jensen S

Breast Cancer: Targets and Therapy 2015, 7:163-164

Published Date: 29 June 2015

Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

Schaffran T, Jiang N, Bergmann M, Küstermann E, Süss R, Schubert R, Wagner FM, Awad D, Gabel D

International Journal of Nanomedicine 2014, 9:3583-3590

Published Date: 29 July 2014

The impact of hypoxia in pancreatic cancer invasion and metastasis

Yuen A, Díaz B

Hypoxia 2014, 2:91-106

Published Date: 16 July 2014

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis

Corbalan JJ, Medina C, Jacoby A, Malinski T, Radomski MW

International Journal of Nanomedicine 2012, 7:631-639

Published Date: 7 February 2012

Correspondence between general practitioner-reported medication use and timing of prescription dispensation

Johannesdottir SA, Mægbæk ML, Hansen JG, Lash TL, Pedersen L, Ehrenstein V

Clinical Epidemiology 2012, 4:13-18

Published Date: 5 January 2012

Biomimetic component coating on 3D scaffolds using high bioactivity of mesoporous bioactive ceramics

Yun HS, Kim SH, Khang DW, Choi JI, Kim HH, Kang MJ

International Journal of Nanomedicine 2011, 6:2521-2531

Published Date: 21 October 2011

Survival of women with breast cancer in central and northern Denmark, 1998–2009

Lietzen LW, Sørensen GV, Ording AG, Garne JP, Christiansen P, Nørgaard M, Jacobsen J

Clinical Epidemiology 2011, 3:35-40

Published Date: 21 July 2011

Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom

Peter Layer, Jutta Keller, Helena Loeffler, Andreas Kreiss

Therapeutics and Clinical Risk Management 2007, 3:107-118

Published Date: 15 March 2007